Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 442

Results For "C"

10342 News Found

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO
People | January 24, 2024

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO

He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom


Aster DM Healthcare gets shareholders nod to separate the GCC business
News | January 24, 2024

Aster DM Healthcare gets shareholders nod to separate the GCC business

The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years


Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr
News | January 23, 2024

Cipla posts Q3 FY24 consolidated PAT at Rs. 1,055.90 Cr

Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023


Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat
Clinical Trials | January 23, 2024

Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial


EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome
Drug Approval | January 23, 2024

EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome

GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023


European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis
Clinical Trials | January 23, 2024

European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis

The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union


Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
News | January 23, 2024

Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr

Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023


Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr
News | January 23, 2024

Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr

Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023


AstraZeneca Pharma India receives permission to import new drug
News | January 22, 2024

AstraZeneca Pharma India receives permission to import new drug

The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India